Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosis.
Matte A, Wilson AB, Gevi F, Federti E, Recchiuti A, Ferri G, Brunati AM, Pagano MA, Russo R, Leboeuf C, Janin A, Timperio AM, Iolascon A, Gremese E, Dang L, Mohandas N, Brugnara C, De Franceschi L. Matte A, et al. Among authors: federti e. JCI Insight. 2023 Oct 23;8(20):e172656. doi: 10.1172/jci.insight.172656. JCI Insight. 2023. PMID: 37676741 Free PMC article.
Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of β-thalassemia.
Matte A, Federti E, Winter M, Koerner A, Harmeier A, Mazer N, Tomka T, Di Paolo ML, De Falco L, Andolfo I, Beneduce E, Iolascon A, Macias-Garcia A, Chen JJ, Janin A, Lebouef C, Turrini F, Brugnara C, De Franceschi L. Matte A, et al. Among authors: federti e. JCI Insight. 2019 Nov 14;4(22):e130111. doi: 10.1172/jci.insight.130111. JCI Insight. 2019. PMID: 31593554 Free PMC article.
The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model.
Matte A, Federti E, Kung C, Kosinski PA, Narayanaswamy R, Russo R, Federico G, Carlomagno F, Desbats MA, Salviati L, Leboeuf C, Valenti MT, Turrini F, Janin A, Yu S, Beneduce E, Ronseaux S, Iatcenko I, Dang L, Ganz T, Jung CL, Iolascon A, Brugnara C, De Franceschi L. Matte A, et al. Among authors: federti e. J Clin Invest. 2021 May 17;131(10):e144206. doi: 10.1172/JCI144206. J Clin Invest. 2021. PMID: 33822774 Free PMC article.
Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in β-thalassemic mice.
Mattè A, Kosinski PA, Federti E, Dang L, Recchiuti A, Russo R, Siciliano A, Riccardi V, Janin A, Mucci M, Leboeuf C, Iolascon A, Brugnara C, De Franceschi L. Mattè A, et al. Among authors: federti e. Haematologica. 2023 Sep 1;108(9):2535-2541. doi: 10.3324/haematol.2022.282614. Haematologica. 2023. PMID: 36794508 Free PMC article. No abstract available.
Erythrocyte pyruvate kinase activation in red cell disorders.
Matte A, Federti E, De Franceschi L. Matte A, et al. Among authors: federti e. Curr Opin Hematol. 2023 May 1;30(3):93-98. doi: 10.1097/MOH.0000000000000758. Epub 2023 Feb 9. Curr Opin Hematol. 2023. PMID: 36853806 Review.
In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell-Related Injury.
Federti E, Matte A, Recchiuti A, Garello F, Ghigo A, El Nemer W, Terreno E, Amoresano A, Mattoscio D, Turrini F, Lebouef C, Janin A, Pantaleo A, Russo R, Marin M, Iatcencko I, Riccardi V, Siciliano A, Iolascon A, Brugnara C, De Franceschi L. Federti E, et al. Hemasphere. 2023 Feb 28;7(3):e848. doi: 10.1097/HS9.0000000000000848. eCollection 2023 Mar. Hemasphere. 2023. PMID: 36874380 Free PMC article.
Resolution of sickle cell disease-associated inflammation and tissue damage with 17R-resolvin D1.
Matte A, Recchiuti A, Federti E, Koehl B, Mintz T, El Nemer W, Tharaux PL, Brousse V, Andolfo I, Lamolinara A, Weinberg O, Siciliano A, Norris PC, Riley IR, Iolascon A, Serhan CN, Brugnara C, De Franceschi L. Matte A, et al. Among authors: federti e. Blood. 2019 Jan 17;133(3):252-265. doi: 10.1182/blood-2018-07-865378. Epub 2018 Nov 7. Blood. 2019. PMID: 30404812 Free PMC article.
28 results